Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Eisai’s 2008 Eribulin NDA Plan Foiled; Beat To The Punch By Bristol-Myers Squibb Drug

This article was originally published in The Pink Sheet Daily

Executive Summary

Ixempra already cleared for identical breast cancer indication.

You may also be interested in...

Eisai Strengthens Oncology Position With $3.9 Billion MGI Pharma Acquisition

MGI sale comes less than two weeks after the biopharma said it was exploring "strategic alternatives."

Eisai’s Perampanel Filing Set Back On Phase III Efficacy Data In Parkinson’s Disease

Japanese drug maker says it now plans to file the AMPA receptor antagonist in fiscal fourth quarter 2008, not fiscal 2007.

FCPA In The China Framework Warrants Special Attention

The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts